Novo Nordisk India has received regulatory approval for its drug Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults with liver fibrosis. This marks the first GLP-1 receptor agonist approved in India for this specific liver condition. The company aims to address the rising burden of fatty liver disease in the country, where treatment options have historically been limited.
Novo Nordisk India has secured a significant regulatory clearance from the Central Drugs Standard Control Organization (CDSCO) for its drug, Wegovy (semaglutide injection 2.4 mg). The approval allows the medication to be used for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults who are suffering from moderate to advanced liver fibrosis.
Expanding Beyond Weight Management
Wegovy is globally recognized for its role in weight management. With this new indication, it becomes the first GLP-1 receptor agonist to receive both international and local regulatory approval specifically for treating this liver condition. MASH is a progressive form of fatty liver disease characterized by the buildup of fat in the liver, which causes inflammation and can eventually lead to permanent tissue damage or fibrosis.
Addressing the Liver Disease Challenge in India
The medical burden of fatty liver disease in India is substantial, with industry data suggesting that a large portion of the population is affected. Because MASH often co-occurs with obesity and other metabolic issues, the approval offers a multi-faceted treatment approach. Vikrant Shrotriya, the Managing Director of Novo Nordisk India, noted that the lack of approved medical therapies for MASH has been a long-standing challenge for healthcare providers in the region. By providing a new therapeutic avenue, the company aims to help patients manage both the liver condition and associated metabolic risks, such as cardiovascular complications, which are often linked to MASH.
Strategic Implications and Next Steps
For investors and the healthcare sector, the key monitorable will be how quickly the company can integrate this new indication into the Indian market and the adoption rate among specialists such as hepatologists and endocrinologists. While this approval strengthens the company’s portfolio in the chronic metabolic disease segment, the ultimate commercial impact will depend on factors like pricing strategies, patient accessibility, and the competitive landscape for liver-focused therapies. As the company rolls out this new treatment option, market observers will look for updates on supply chain readiness and clinical outreach programs aimed at increasing awareness of MASH screening among the Indian medical community.